307 related articles for article (PubMed ID: 36537918)
21. Targeting compensatory MEK/ERK activation increases JAK inhibitor efficacy in myeloproliferative neoplasms.
Stivala S; Codilupi T; Brkic S; Baerenwaldt A; Ghosh N; Hao-Shen H; Dirnhofer S; Dettmer MS; Simillion C; Kaufmann BA; Chiu S; Keller M; Kleppe M; Hilpert M; Buser AS; Passweg JR; Radimerski T; Skoda RC; Levine RL; Meyer SC
J Clin Invest; 2019 Mar; 129(4):1596-1611. PubMed ID: 30730307
[TBL] [Abstract][Full Text] [Related]
22. Janus kinase (JAK) inhibitors in the treatment of neoplastic and inflammatory disorders.
Roskoski R
Pharmacol Res; 2022 Sep; 183():106362. PubMed ID: 35878738
[TBL] [Abstract][Full Text] [Related]
23. Discovery and evaluation of ZT55, a novel highly-selective tyrosine kinase inhibitor of JAK2
Hu M; Xu C; Yang C; Zuo H; Chen C; Zhang D; Shi G; Wang W; Shi J; Zhang T
J Exp Clin Cancer Res; 2019 Feb; 38(1):49. PubMed ID: 30717771
[TBL] [Abstract][Full Text] [Related]
24. Epigenetic deregulated miR-375 contributes to the constitutive activation of JAK2/STAT signaling in myeloproliferative neoplasm.
Yin LH; Zheng XQ; Li HY; Bi LX; Shi YF; Ye AF; Wu JB; Gao SM
Leuk Res; 2015 Apr; 39(4):471-8. PubMed ID: 25666256
[TBL] [Abstract][Full Text] [Related]
25. Myeloproliferative neoplasms: JAK2 signaling pathway as a central target for therapy.
Pasquier F; Cabagnols X; Secardin L; Plo I; Vainchenker W
Clin Lymphoma Myeloma Leuk; 2014 Sep; 14 Suppl():S23-35. PubMed ID: 25486952
[TBL] [Abstract][Full Text] [Related]
26. New JAK2 inhibitors for myeloproliferative neoplasms.
Quintás-Cardama A; Verstovsek S
Expert Opin Investig Drugs; 2011 Jul; 20(7):961-72. PubMed ID: 21521147
[TBL] [Abstract][Full Text] [Related]
27. Myeloproliferative and lymphoproliferative disorders: State of the art.
Rumi E; Baratè C; Benevolo G; Maffioli M; Ricco A; Sant'Antonio E
Hematol Oncol; 2020 Apr; 38(2):121-128. PubMed ID: 31833567
[TBL] [Abstract][Full Text] [Related]
28. JAK-STAT inhibition reduces endothelial prothrombotic activation and leukocyte-endothelial proadhesive interactions.
Beckman JD; DaSilva A; Aronovich E; Nguyen A; Nguyen J; Hargis G; Reynolds D; Vercellotti GM; Betts B; Wood DK
J Thromb Haemost; 2023 May; 21(5):1366-1380. PubMed ID: 36738826
[TBL] [Abstract][Full Text] [Related]
29. JAK-mutant myeloproliferative neoplasms.
Levine RL
Curr Top Microbiol Immunol; 2012; 355():119-33. PubMed ID: 21823028
[TBL] [Abstract][Full Text] [Related]
30. Activation of JAK/STAT Signaling in Megakaryocytes Sustains Myeloproliferation
Woods B; Chen W; Chiu S; Marinaccio C; Fu C; Gu L; Bulic M; Yang Q; Zouak A; Jia S; Suraneni PK; Xu K; Levine RL; Crispino JD; Wen QJ
Clin Cancer Res; 2019 Oct; 25(19):5901-5912. PubMed ID: 31217200
[TBL] [Abstract][Full Text] [Related]
31. CHZ868, a Type II JAK2 Inhibitor, Reverses Type I JAK Inhibitor Persistence and Demonstrates Efficacy in Myeloproliferative Neoplasms.
Meyer SC; Keller MD; Chiu S; Koppikar P; Guryanova OA; Rapaport F; Xu K; Manova K; Pankov D; O'Reilly RJ; Kleppe M; McKenney AS; Shih AH; Shank K; Ahn J; Papalexi E; Spitzer B; Socci N; Viale A; Mandon E; Ebel N; Andraos R; Rubert J; Dammassa E; Romanet V; Dölemeyer A; Zender M; Heinlein M; Rampal R; Weinberg RS; Hoffman R; Sellers WR; Hofmann F; Murakami M; Baffert F; Gaul C; Radimerski T; Levine RL
Cancer Cell; 2015 Jul; 28(1):15-28. PubMed ID: 26175413
[TBL] [Abstract][Full Text] [Related]
32. Rationale for targeting the PI3K/Akt/mTOR pathway in myeloproliferative neoplasms.
Bartalucci N; Guglielmelli P; Vannucchi AM
Clin Lymphoma Myeloma Leuk; 2013 Sep; 13 Suppl 2():S307-9. PubMed ID: 24290217
[TBL] [Abstract][Full Text] [Related]
33. SHP2 inhibition displays efficacy as a monotherapy and in combination with JAK2 inhibition in preclinical models of myeloproliferative neoplasms.
Pandey G; Mazzacurati L; Rowsell TM; Horvat NP; Amin NE; Zhang G; Akuffo AA; Colin-Leitzinger CM; Haura EB; Kuykendall AT; Zhang L; Epling-Burnette PK; Reuther GW
Am J Hematol; 2024 Jun; 99(6):1040-1055. PubMed ID: 38440831
[TBL] [Abstract][Full Text] [Related]
34. Cardiovascular Events: A Challenge in JAK2-positive Myeloproliferative Neoplasms.
Haybar H; Khodadi E; Shahjahani M; Saki N
Cardiovasc Hematol Disord Drug Targets; 2017; 17(3):161-166. PubMed ID: 29086702
[TBL] [Abstract][Full Text] [Related]
35. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia.
Pikman Y; Lee BH; Mercher T; McDowell E; Ebert BL; Gozo M; Cuker A; Wernig G; Moore S; Galinsky I; DeAngelo DJ; Clark JJ; Lee SJ; Golub TR; Wadleigh M; Gilliland DG; Levine RL
PLoS Med; 2006 Jul; 3(7):e270. PubMed ID: 16834459
[TBL] [Abstract][Full Text] [Related]
36. Recent patents of gene mutation relative to JAK/STAT pathway and their implication in myeloproliferative diseases.
Shi Y; Xu C
Recent Pat DNA Gene Seq; 2008; 2(3):209-13. PubMed ID: 19075958
[TBL] [Abstract][Full Text] [Related]
37. Current approaches to challenging scenarios in myeloproliferative neoplasms.
Zimran E; Hoffman R; Kremyanskaya M
Expert Rev Anticancer Ther; 2018 Jun; 18(6):567-578. PubMed ID: 29575945
[TBL] [Abstract][Full Text] [Related]
38. Therapy with JAK2 inhibitors for myeloproliferative neoplasms.
Santos FP; Verstovsek S
Hematol Oncol Clin North Am; 2012 Oct; 26(5):1083-99. PubMed ID: 23009939
[TBL] [Abstract][Full Text] [Related]
39. Increased neutrophil extracellular trap formation promotes thrombosis in myeloproliferative neoplasms.
Wolach O; Sellar RS; Martinod K; Cherpokova D; McConkey M; Chappell RJ; Silver AJ; Adams D; Castellano CA; Schneider RK; Padera RF; DeAngelo DJ; Wadleigh M; Steensma DP; Galinsky I; Stone RM; Genovese G; McCarroll SA; Iliadou B; Hultman C; Neuberg D; Mullally A; Wagner DD; Ebert BL
Sci Transl Med; 2018 Apr; 10(436):. PubMed ID: 29643232
[TBL] [Abstract][Full Text] [Related]
40. JAK2 mutations and clinical practice in myeloproliferative neoplasms.
Tefferi A
Cancer J; 2007; 13(6):366-71. PubMed ID: 18032973
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
